The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...

Novavax, which makes the Nuvaxovid vaccine used to treat Covid-19, posted huge sales gains for the past three years during the height of the pandemic. But the company is now facing serious ...

Writing in JAMA, four former government officials warn that the Trump administration’s involvement in delaying the approval ...

Nuvaxovid lasts six months under the same conditions. “The Novavax vaccine is much less demanding,” Fei Wen, a chemical engineer at the University of Michigan, told The Daily Beast.

NUVAXOVID’s approval is also a major milestone for the U.S. population and the healthcare industry, as it is the first and only full FDA approval for a non-mRNA, protein-based COVID-19 vaccine.

May 19, 2025 – The FDA has approved the Novavax COVID-19 vaccine, a protein-based alternative to mRNA shots, with some limits on who can get it. The vaccine, called Nuvaxovid, is mainly intended ...

Nuvaxovid is supplied in a single-dose prefilled syringe containing 0.5mL suspension for intramuscular injection; it should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F).

As for Nuvaxovid, this standalone Novavax Covid-19 vaccine received its FDA approval in May, a regulatory decision that covers its use in those age 65 and older.

About Nuvaxovid™ (NVX-CoV2373) NVX-CoV2373 is a protein-based vaccine made by creating copies of the surface spike protein of SARS-CoV-2 that causes COVID.

Nuvaxovid's FDA Scare In late April 2025, Novavax revealed that it believes the FDA is asking for a post‑marketing commitment in its Biologics License Application for Nuvaxovid, noting ...

Novavax’s shares traded nearly 20% in pre-market trading at the time of writing.. The long-awaited approval for Nuvaxovid restricts its use to adults aged 65 and older. People aged between 12 ...